This was an interesting week for the global healthcare sector. Scientists in Japan aim to treat spinal cord injuries using reprogrammed stem cells, while a clinical trial of antibodies to treat leukemia was put on hold after the death of two patients.
In Mexico, a consulting company claims half of Mexico’s states fail at transparency in healthcare, doctors link sexual dysfunction with overweight and obesity in men and Guadalajara hosted the International Congress on Medical Advances focused on robotics.
In case you missed it, this is what made the headlines over the past week.
- The Mexican College of Surgery for Obesity and Metabolic Diseases linked sexual dysfunction with obesity and overweight. It is estimated that 79 percent of all men with erectile dysfunction have a body mass index (BMI) of 25 kg/m2 or more. A BMI in the range of 25-30 kg/m2 is associated with 1.5 times more risk of sexual dysfunction, while a range of over 30 kg/m2 ups risk threefold.
- Half of Mexico’s states fail at transparency in healthcare services, according to consulting company Aregional. The five entities with the lowest scores in transparency are Durango, Guerrero, San Luis Potosi, Tabasco and Chiapas.
- GINmedical, part of GINgroup, allied with State of Mexico Healthcare University (UNSA) to provide students with better tools to learn medicine, nutrition, rehabilitation and nursery. These tools will be provided at the group’s Centro Medico GIN Toluca.
- Hospital Civil de Guadalajara hosted the 21st International Congress on Medical Advances, which among other topics addressed the potential of robotic surgery in Mexico and the benefits it can bring to patients.
- Flex LTD will invest over US$65 million in its plant in Aguascalientes to expand production lines. The company manufactures devices for the health, automotive, renewable energy, aeronautics, military, communications and construction industries, among others.
- Japanese scientists plan to treat spinal cord injuries in humans using reprogrammed stem cells. These have already been used to regenerate spinal neurons in monkey spinal cords.
- Xencor’s Phase I trial of antibodies for acute myeloid leukemia (AML) is put on hold after the death of two patients due to drug-related complications. Xencor’s drug was part of a US$2.5 billion joint project with Novartis.
Industry Analyst and Journalist at Mexico Business Publishing